Alejandro Martínez-Pradeda
Alejandro Martínez-Pradeda is an expert in Pharmacy at Complexo Hospitalario Universitario A Coruña (Spain). Alejandro Martínez-Pradeda has authored 12 publications, the most recent in 2025. SLR score: 41 (community average: 125). How the SLR is computed.
LeadR Profile
Pharmacy
Subspecialties: Biochemistry - Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2019 - 2025Complexo Hospitalario Universitario A Coruña - Farmacéutico Interno Residente
2019 - 2025
Complexo Hospitalario Universitario A Coruña - Farmacéutico adjunto - área oncohematología
2023 - 2025
Centro Oncológico de Galicia
2024 - 2025
Number : 12
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Optimal Thromboprophylaxis in Laparoscopic Bariatric Surgery in a Private Third-Level Center in Mexico City. PMID 40704261 — enoxaparin, embolism, heparin, bariatric surgery, pulmonary embolism, venous thromboembolism | Cureus | 2025 | 0 |
| The STAT3/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report. PMID 40703266 — radiotherapy, cells, lung, silymarin, silybin, brain, neoplasms, carcinoma, non-small-cell lung, adenocarcinoma of lung, immunotherapy, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, therapeutics | Front Med (Lausanne) | 2025 | 1 |
| Application of instant assembly of collagen to bioprint cardiac tissues. PMID 40520649 — cells, bioprinting, collagen, tissue engineering, tissues | APL Bioeng | 2025 | 0 |
| Real-World Safety Profile of Ibrutinib in Chronic Lymphocytic Leukemia: A Focus on Adverse Events, Discontinuations, and Effectiveness Outcomes. PMID 40413564 — comorbidity, hematology, safety, neoplasms, leukemia, lymphocytic, chronic, b-cell, leukemia, drug therapy, leukemia, lymphoid, drug-related side effects and adverse reactions, drug tapering, therapeutics | Ann Pharmacother | 2025 | 0 |
| Macromolecular crowding-based biofabrication utilizing unmodified extracellular matrix bioinks. PMID 40268621 — cells, intestines, bioprinting, biocompatible materials, solutions, crowding, tissues, gels, extracellular matrix | Acta Biomater | 2025 | 0 |
LeadR Networks
Main global connection map